You are here

  • Home
  • Archive
  • Volume 72, Issue 10
  • Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome

Authors

  • Heleen D de Koning Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of Dermatology, Nijmegen Centre for Molecular Life Sciences (NCMLS), Nijmegen, The Netherlands Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of General Internal Medicine, N4i Centre for Immunodeficiency and Autoinflammation, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Joost Schalkwijk Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of Dermatology, Nijmegen Centre for Molecular Life Sciences (NCMLS), Nijmegen, The Netherlands Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Johanna van der Ven-Jongekrijg Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Monique Stoffels Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of General Internal Medicine, N4i Centre for Immunodeficiency and Autoinflammation, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Jos W M van der Meer Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of General Internal Medicine, N4i Centre for Immunodeficiency and Autoinflammation, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  • Anna Simon Department of Dermatology, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of General Internal Medicine, N4i Centre for Immunodeficiency and Autoinflammation, Nijmegen, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Heleen Dian de Koning, Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands; h.dekoning{at}derma.umcn.nl
View Full Text

Citation

de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al
Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome
Annals of the Rheumatic Diseases 2013;72:1634-1638.

Publication history

  • Accepted September 23, 2012
  • First published October 19, 2012.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions